DWTX
NASDAQ · Biotechnology
Dogwood Therapeutics Inc
$3.17
+0.00 (+0.00%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.10M | 11.96M | 10.98M |
| Net Income | 3.15M | 2.42M | 2.50M |
| EPS | — | — | — |
| Profit Margin | 26.0% | 20.2% | 22.8% |
| Rev Growth | +0.7% | +19.7% | +24.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 49.65M | 44.85M | 51.81M |
| Total Equity | 53.46M | 61.84M | 55.56M |
| D/E Ratio | 0.93 | 0.73 | 0.93 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.53M | 4.37M | 3.74M |
| Free Cash Flow | 1.56M | 1.43M | 1.67M |